

ersonal use only



September Quarterly Shareholder update

Gary Phillips, CEO
30th October 2024

Forward looking statement

This document contains forward-looking statements, including statements concerning Syntara's future financial position, plans, and the potential of its products and product candidates, which are based on information and assumptions available to Syntara as of the date of this document. Actual results, performance or achievements could be significantly different from those expressed in, or implied by, these forward-looking statements. All statements, other than statements of historical facts, are forward-looking statements.

These forward-looking statements are not guarantees or predictions of future results, levels of performance, and

involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results to differ materially from those expressed in the statements contained in this document. For example, despite our efforts there is no certainty that we will be successful in developing or partnering any of the products in our pipeline on commercially acceptable terms, in a timely fashion or at all. Except as required by law we undertake no obligation to update these forward-looking statements as a result of new information, future events or otherwise.



Investment Highlights



Australian-founded **clinical stage drug developer**.



Backed **by specialist healthcare investors** – 54% institutional.



Focus on first-in-class and best-in-class drugs backed by **in house long-life patent portfolio**.



Funded to mid-2025 with **near term data to drive value** over 12-18 months.



Multiple shots on goal from additional Phase 2, Phase 1 and preclinical assets.



Experienced team with **proven track record** in licensing deals – \$100m raised.



Three Phase 2 studies in **blood cancer indications** with addressable market value >\$4.5 bn.



\$8.5m in non-dilutive grant funding awarded in last 3 years.

September Quarter Highlights

- **Phase 2 blood cancer trial recruitment target achieved as 15th patient dosed with 12 patients exceeding one month treatment – we plan to release interim results in December 2024**
- **Researchers at Heidelberg University to take SNT-5505 into the clinic for the blood cancers myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) with A\$2.5m funding from Deutsche Krebshilfe (German Cancer Aid)**
- **Tim Luscombe appointed Chief Financial Officer**
- **\$5 million raised to provide essential funding for the Company's Phase 2 clinical trials**

Shareholders & cash

Financial Information (ASX: SNT)

| | |
|---------------------------------------------------|-----------|
| Share price – 29 October 2024 | \$0.044 |
| Market Cap | A\$60.42m |
| Proforma cash balance (30 June 2024) ¹ | A\$10.4m |
| Enterprise value | A\$50.02m |

Note:


1. Proforma cash of \$13.0m includes: cash (\$4.34m); 2024 R&D tax credit (\$4.56m); return of security deposit (\$0.9m), \$0.6 million of proceeds from the sale of the MBU.

Institutional Ownership

30 June 24

| | |
|----------------------------------------|------------|
| D&A Income Limited | 20% |
| Platinum Investment Management Limited | 15% |
| BVF Partners LP | 9% |
| Total Institutional Ownership | 54% |

Share Price & Volume - YTD




*22 January volume 78.66m — crossing of stock between institutions after closure of fund

Syntara is the global leader in lysyl oxidase chemistry and biology

Multi year research program leveraged with extensive scientific collaborations worldwide has delivered three drugs now in phase 1c/2 studies

Lysyl oxidases mediate the final stage in fibrosis



Lysyl oxidase inhibition provides a true anti-fibrotic therapy, directly addressing the tissue stiffening that occurs due to increases in collagen and number of cross-links.

SNT-5505 in Oncology

- Clinical PoC: reduction of bone marrow collagen fibrosis grade in 45% of evaluable myelofibrosis patients in 6-month Phase 2 study
- Excellent clinical safety and tolerability with a complementary mode of action to current standard of care
- INDs approved for myelofibrosis and hepatocellular carcinoma
- Potential in haematological indications such as MDS as well as solid tumours; two Nature publications
- Patent priority date of 2018 provides extended IP coverage

Topical pan-LOX inhibitors in Skin Scarring

- Clinical PoC: significant reduction of collagen and good safety in 3-month placebo-controlled Phase 1c study in patients with established scars
- Lead and back up compounds to support studies in multiple scar types (prevention of scar formation and modification of existing scars) in topical and oral dosage form
- Strong preclinical evidence in models of skin fibrosis and scarring; Nature publication
- Patent priority date of 2019 provides extended IP coverage


Myelofibrosis

A rare type of bone marrow cancer that disrupts the body's normal production of blood cells

Key Facts

- Affects ~15 in 1m people worldwide
- Age of onset typically from age 50; 5 years median survival
- 11% transformation to leukemia
- Reduced red blood cells can cause extreme tiredness (fatigue) or shortness of breath
- Reduced white blood cells can lead to an increased number of infections
- Reduced platelets can promote bleeding and/or bruising
- Spleen increases blood cell production and becomes enlarged
- Other common symptoms include fever, night sweats, and bone pain.

Primary Myelofibrosis is characterised by a build up of scar tissue (fibrosis) in bone marrow reducing the production of blood cells.



Current standard of care (SoC): JAK inhibition

- Symptomatic relief plus some limited survival improvement.
- 75% discontinuation at 5 years
- Median overall survival is 14 – 16 months after discontinuation

SNT-5505

In contrast to SoC SNT-5505 intervenes at the source, clearing fibrosis from the bone marrow and enabling the production of healthy blood cells to resume

Clinical positioning

- Distinct mode of action, improved tolerability and a profile suitable for combination with SoC
- In addition to symptomatic relief, potential for disease modification.

Commercial Opportunity

- Current SoC; revenue ~US\$1b per annum
- Recent history of biotech exits in excess of US\$1.7b

SNT-5505 Phase 2a trial part 1; Monotherapy in JAK inhibitor treatment failures


Demonstrates improvements in fibrosis grade, excellent safety profile and promising signs of clinical activity

ersonal use only

| Study Design | Endpoints | Trial Outlooks |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <ul style="list-style-type: none"> • IND approved Q3 2020 • Open label Phase 2a • 200mg BD dose (>90% inhibition of LOX enzyme) • 21 trial sites in Australia, South Korea, Taiwan and USA • Recruited 24 patients who were non responsive or inappropriate for JAKi treatment • 13 patients completed 24 weeks of treatment | <ul style="list-style-type: none"> • SNT-5505 has been well tolerated • Majority of AEs were mild and not related to treatment • 11 patients dropped out of the study, none due to treatment related AEs | <ul style="list-style-type: none"> • 5/11 evaluable patients had improved bone marrow fibrosis scores of ≥ 1 grade • 5/13 had an improvement in symptom score of >20% • 9/13 had stable/improved hemoglobin (Hb) counts • 10/13 had stable/improved platelet counts • No spleen volume response (SVR35) was identified |

Phase 2a study; SNT-5505 in patients on a stable dose of JAK inhibitor

Fastest route to meaningful data with no dose escalation and utilising existing trial infrastructure



[ClinicalTrials.gov ID NCT04676529](https://clinicaltrials.gov/ct2/show/study/NCT04676529)

Safety Monitoring Committee (SMC) – 30 May 2024

- SMC consists of all Study Investigators, CRO Medical Monitor and Sponsor representative.
- 10 patients reviewed, 5/10 at 3 months
- Unanimous agreement from all voting members to continue the study

* JAKi – Janus Kinase inhibitor, RUX – Ruxolitinib, MF myelofibrosis, ET Essential Thrombocythaemia, PV polycythaemia vera, INT intermediate, BMF bone marrow fibrosis, PK pharmacokinetics, PD pharmacodynamics, SVR spleen volume response, IWG International Working Group Myeloproliferative Neoplasms

Study Plan

- 19 clinical trial sites
- Recruitment started 13 Dec 2023
- **Fully recruited (August 2024)**

Interim 6 months data targeted for Dec 2024 at American Society of Hematology

- Top line data expected mid 2025

Interim data to drive FDA discussion on pivotal study design and potential partnering interest

Strong interest in myelofibrosis assets from strategics

Target / Acquiror



| Date of Announcement | Feb-2024 | June-2023 | July-2022 |
|------------------------------------------|--------------------------------------------|--------------------------|----------------------------------|
| Drug Name | Pelabresib | Pacritinib | Momelotinib |
| Lead Indication / Phase (at transaction) | Myelofibrosis (Successful Phase 3 studies) | Myelofibrosis (Marketed) | Myelofibrosis (FDA Filed – June) |
| Deal Type | Acquisition | Acquisition | Acquisition |
| Upfront / Milestones (USD) | US\$2.9B | US\$1.7B | US\$1.9B |
| Earnout Payments / Royalty Rate (%) | Subject to regulatory approvals | None | None |

ersonal use only

Potential to deliver near term value

Pipeline creates multiple opportunities in high value markets

| Drug Candidate | Indication | Phase | Anticipated Upcoming Milestones | Addressable market (US\$) |
|--------------------------------------------|---------------------------------------------------------------------------|------------|------------------------------------------------------|-----------------------------------|
| SNT-5505 | Myelofibrosis | Phase 2 | Interim 6 month data December 2024 | ~\$1 billion¹ |
| | Myelodysplastic Syndrome Low & intermediate Risk + High risk trials | Phase 1c/2 | Low/Int Risk Data H2 25 High Risk – Grant Pending | ~\$3.2 billion² |
| Oral and Topical Pan-LOX inhibitors | Scar prevention | Phase 2 | Data H2 2025 | ~\$3.5 billion³ |
| | Modification of scarring process | Phase 1c | Pilot study in keloid scars planned | ~\$3.5 billion⁴ |
| SNT-4728 | IRBD and Parkinson's Disease | Phase 2 | Data H2 2025 | ~\$3.5 billion⁵ |


1) MF: Addressable market, The Myelofibrosis market size across the 8MM was valued at \$2.39 billion in 2021 : <https://www.globaldata.com/store/report/myelofibrosis-market-analysis/>
2) MDS: Addressable market, MYELODYSPLASTIC SYNDROME TREATMENT MARKET ANALYSIS, <https://www.coherentmarketinsights.com/market-insight/myelodysplastic-syndrome-treatment-market-775>
3) Scar Prevention: Global Scar Market 2020 page 40 and 71; Total scar treatment market in 2019 exceeded US\$19b. Keloid and hypertrophic scar segment ~US\$3.5b
4) Scar modification: Addressable market, Global Scar Market 2020 page 40 and 71. Total scar treatment market in 2019 exceeded US\$19b. Keloid and hypertrophic scar segment ~US\$3.5b
5) IRBD / Parkinson's Addressable market, Parkinson's Disease market size across the 7MM was valued at \$3.4 billion in 2019 and is expected to achieve a CAGR of more than 6% during 2019-2029. <https://www.globaldata.com/store/report/parkinsons-disease-major-market-analysis/>

Personal use only

Recent & anticipated news flow

Strong and growing pipeline with advancement in studies expected to provide value inflection points

ersonal use only





Syntara Limited ABN 75 082 811 630



Gary Phillips
Chief Executive Officer
gary.phillips@syntaraTX.com.au

www.syntaraTX.com.au

